FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

	OMB Number:	3235-0287								
	Estimated average burden									
- 1	hours por rosponso:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Carmichael Clare					<u>A</u>	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN									all applica Director Officer (Officer (give title		10% Ov Other (s	vner	
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET					02	3. Date of Earliest Transaction (Month/Day/Year) 02/27/2017									EVP, Chief HR Officer					
(Street) NEW HAVEN CT 06510 (City) (State) (Zip)				_	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person												ı			
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				action	ion 2A. Deemed Execution Date, if any			3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amount Securities Beneficiall		s Illy	Form (D) or	Direct Indirect	7. Nature of Indirect Beneficial		
					(IV	(Month/Day/Year)		8) Code	v	Amount	(A) or (D)	Price		Reported Transacti				Ownership (Instr. 4)		
Common Stock, par value \$.0001 per share 02/27/2				7/2017)17		S		860(1)	D	\$131.	\$131.2 ⁽²⁾		,980		D				
Common Stock, par value \$.0001 per share 02/28/2				3/2017	017			S		915(1)	D	\$131.7	131.71 ⁽²⁾ 3		3,065		D			
Common Stock, par value \$.0001 per share 02/28/2				3/2017	017		A		6,500 ⁽³⁾	A	\$0	\$0		39,565		D				
Common Stock, par value \$.0001 per share 03/01/2				1/2017	017			S		404(1)	D	\$132.	\$132.5(4)		39,161		D			
			Table II								posed of, convertib			y O	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,	Code (In				6. Date Exer Expiration I (Month/Day		ate	of Secur Underlyi	ng /e Securit	[3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amour or Number of Shares	er		(Instr. 4)				
Option to Purchase Common	\$131.25	02/28/2017			A		12,800 ⁽⁵⁾		02/28	3/2018	02/28/2027	Stock, par value	1	00	\$0	25,60	0	D		

Explanation of Responses:

- 1. This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$131.00 \$131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 3. Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.
- 4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$132.00 \$132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 5. Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.

Remarks:

Stock

/s/ Michael Greco, Attorney-in-03/01/2017 Fact for Clare Carmichael

** Signature of Reporting Person Date

\$ 0001

per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.